Safety Study of Nicotinamide to Treat Alzheimer's Disease - Full Text View

Purpose

The purpose of this study is to determine whether nicotinamide, or vitamin B3, is safe and effective in the treatment of Alzheimer's disease.

Condition	Intervention	Phase
Alzheimer's Disease	Drug: Nicotinamide Drug: Enduramide placebo	Phase 1 Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Participant, Care Provider, Investigator, Outcomes Assessor Primary Purpose: Treatment
Official Title:	Efficacy of Nicotinamide for the Treatment of Alzheimer's Disease

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease

Drug Information available for: Niacin Niacinamide

Genetic and Rare Diseases Information Center resources: Familial Alzheimer Disease

U.S. FDA Resources

Further study details as provided by Steven Schreiber, University of California, Irvine:

Primary Outcome Measures:

Alzheimer's Disease Assessment Scale-Cognitive Subscale [ Time Frame: Baseline, 6 wk, 12 wk, 18 wk, 24 wk ]


Enrollment:	50
Actual Study Start Date:	January 2008
Study Completion Date:	July 2014
Primary Completion Date:	July 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 Subjects will receive experimental drug in a blinded fashion.	Drug: Nicotinamide 1500 mg twice a day for 6 months Other Name: Enduramide
Placebo Comparator: 2 Identical in size, shape and color to experimental drug.	Drug: Enduramide placebo 1 tab twice a day

Detailed Description:

The goal of this proposal is to show that, nicotinamide (NA), a B3 vitamin, is safe and effective for the treatment of patients with mild to moderate Alzheimer's disease (AD). NA is known to block the ability of certain proteins to regulate other proteins by removing their acetyl groups. Recent evidence has demonstrated that inhibitors such as NA prevent nerve cell degeneration in models of Huntington's disease (HD), Parkinson's disease and Lou Gehrig's disease (or ALS). Despite these beneficial effects in many different animal models, there have been no studies to date using these inhibitors in AD. In some of our recent studies we found that the potent inhibitor, NA, significantly improves learning and memory in transgenic mice that develop AD. NA treatment also resulted in striking changes in tau, a protein that abnormally accumulates in AD. NA has been extensively used in clinical studies over the last 40 years and is generally safe and well-tolerated. As NA is a safe and readily available vitamin supplement, our recent results provide a strong argument for a study of NA in patients with AD. We therefore propose to treat 50 patients with mild to moderate AD with either NA (1500 milligrams twice a day) or an identical but inactive drug (placebo) for 24 weeks. At 6 week intervals we will assess functions such as learning and memory, and ability to carry out daily activities as well as caregiver reports using standardized tests. We will also perform spinal taps at the beginning and end of the study to measure the level of abnormal tau protein in the cerebrospinal fluid. Blood tests will periodically be done to assess liver function and complete blood counts. The results of this study may provide the basis for a more extensive study of NA for the treatment of mild to moderate AD.

Eligibility


Ages Eligible for Study:	50 Years to 95 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of probable AD according to DSM-IV criteria
Mild to moderate dementia based on Mini-Mental State Examination [MMSE] score between 13-25
Minimum age 50 years
Brain imaging (computed tomographic scan or magnetic resonance image) within 12 months consistent with a diagnosis of probable AD
Hachinski Ischemic Score of <4.
Stable doses of concomitant medications, including cholinesterase inhibitors (ChEIs) and/or memantine.

Exclusion Criteria:

Dementia due to another cause
Other neurological or psychiatric diseases
Pseudodementia
Unstable medical condition
Initial treatment within 30 days of screening with a ChEI, memantine or any investigational drug
History of alcoholism, drug abuse, liver disease, peptic ulcer disease
Pregnancy, or the potential to become pregnant.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00580931

Locations


United States, California
UC Irvine School of Medicine
Irvine, California, United States, 92697

Sponsors and Collaborators

University of California, Irvine

Alzheimer's Association

Investigators


Principal Investigator:	Steven S Schreiber, MD	Regents of the University of California

More Information


Responsible Party:	Steven Schreiber, Professor of Neurology, University of California, Irvine
ClinicalTrials.gov Identifier:	NCT00580931 History of Changes
Other Study ID Numbers:	IIRG-07-61197
Study First Received:	December 24, 2007
Last Updated:	January 23, 2017

Keywords provided by Steven Schreiber, University of California, Irvine:


nutraceutical, dementia, cognition, HDAC inhibitor

Additional relevant MeSH terms:


Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Niacinamide Niacin	Nicotinic Acids Vitamin B Complex Vitamins Micronutrients Growth Substances Physiological Effects of Drugs Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Vasodilator Agents

ClinicalTrials.gov processed this record on June 26, 2017